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We report data about the effects of intraperitoneal (i.p.) injection of
speciﬁc pathogen-free (SPF) porcine Sertoli cells (SeC) encapsulated
into clinical grade alginate-based microcapsules (SeC-MC) on muscles
of chronic and presymptomatic dystrophic, mdx mice. Mdx mouse is
the best characterized animal model of Duchenne muscular dystro-
phy (DMD), an X-linked lethal myopathy due to mutation in the gene
of dystrophin, which is crucial for myoﬁber integrity during muscle
contraction. Our data show that three weeks after i.p. injection of
SeC-MC signiﬁcantly reduced adipose and ﬁbrous tissue deposition,
reduced macrophage inﬁltrate, and reduced numbers of damaged
myoﬁbers are found in muscles of 12-month-old mdx mice, which
reproduce chronic DMD conditions. Compared with muscles of mock-vier Inc. This is an open access article under the CC BY license
/j.biomaterials.2015.10.029
imental Medicine, University of Perugia, Perugia 06132, Italy.
rci).
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S. Chiappalupi et al. / Data in Brief 5 (2015) 1015–10211016treatedmdxmice muscles of SeC-MC-treated mice show upregulation
of the dystrophin paralogue, utrophin which is localized to the per-
iphery of myoﬁbers. Moreover, our data show that i.p. injection of
SeC-MC into presymptomatic, 2-week-old mdx mice, although not
fully preventing myoﬁber degeneration, results in protection against
myoﬁber necrosis and muscle inﬂammation. Extensive discussion of
these data can be found in Ref. [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaTranslational medicine/Preclinical studiesype of data Text ﬁle and ﬁgures
ow data was
acquiredBright ﬁeld microscope Olympus BX51; epiﬂuorescence microscope Leica
DMRB; C-DiGit Blot Scanner (LI-COR)ata format Raw; analyzed
xperimental
factorsIntraperitoneal injection of microencapsulated SPF porcine Sertoli cells (SeC-
MC) in chronic and presymptomatic dystrophic (mdx) mice. Three weeks
after injection, muscles of mock- and SeC-MC-treated mdx mice were ana-
lyzed for several parameters.xperimental
featuresMuscle tissue were formalin-ﬁxed parafﬁn embedded or fresh-frozen for
histology, immunohistochemistry, immunoﬂuorescence or Evans blue dye
(EBD) inﬁltration tests, or were homogenized for western blotting analysis.ata source
locationUniversity of Perugia, Perugia 06132, Italy; IRCCS Fondazione Santa Lucia,
Rome 00143, Italy; La Sapienza University, Rome 00161, Italyata accessibility The data are supplied with this articleDValue of the data
Inﬂammatory events secondary to lack of dystrophin play a major role in the outcome of DMD
pathology [2,3], so that antiinﬂammatory steroids represents the current standard treatment for DMD
patients, albeit with limited efﬁcacy and undesired side effects [4–6].
The therapeutic approaches to DMD proposed so far have revealed intrinsic limitations and/or
require pharmacological immunosuppression, so that combinatorial approaches are encouraged [4].
Here we propose a therapeutic approach that combines the antiinﬂammatory and immunomo-
dulatory properties of Sertoli cells (SeC) with the safety of using microencapsulated cells. We show
that inside the microcapsules SeC act as a “micro-biofactory” and drug delivery system able to
improve muscle morphology and performance by secreting immunomodulatory and trophic factors
[7–9] once injected into the peritoneal cavity of dystrophic mice.
Our data open new perspective in the treatment of DMD and related myopathies.1. Data
We injected microencapsulated Sertoli cells (SeC-MC) or empty microcapsules (E-MC) into the
peritoneal cavity of 12-month-old mdx mice, which reproduce chronic DMD conditions since their
muscles (especially the diaphragms, DIA) progressively accumulate ﬁbrous and adipose tissue [10].
Three weeks after injection, SeC-MC induced a signiﬁcant reduction of fat and ﬁbrous tissue
S. Chiappalupi et al. / Data in Brief 5 (2015) 1015–1021 1017
S. Chiappalupi et al. / Data in Brief 5 (2015) 1015–10211018deposition in muscles (Fig. 1A, B, D, G and I). Moreover, SeC-MC treatment resulted in reduced
macrophage inﬁltrate and muscle damage, as investigated by MAC3 immunohistochemistry in DIA
and Tibialis anterior (TA) muscles (Fig. 1C, D, H and I), and autoﬂuorescence analysis of the Quadriceps
femoris (QF) after Evans blue dye (EBD) injection (Fig. 1E). Compared with muscles of mock-treated
mdx mice, muscles of SeC-MC-treated mdx mice showed upregulated utrophin (3.2-fold increase in
protein amount) (Fig. 1J), which was localized to the periphery of the myoﬁbers (Fig. 1K), a condition
necessary for utrophin to functionally replace dystrophin.
Treatment with SeC-MC in pre-symptomatic 2-week-old mdx mice, which show only minor signs
of muscle degeneration (94.476.1% undamaged myoﬁbers in TA muscles) (Fig. 2A) resulted in not full
prevention but protection against the necrosis of myoﬁbers and muscle inﬂammation, as evidenced
by histological and immunohistochemical analyses performed three weeks after injection (Fig. 2A and
B). Also in this case, utrophin expression resulted increased (about ﬁve-fold increase compared to
mock-treated animals) and localized at the periphery of myoﬁbers (Fig. 2C and D). Incidentally, our
data show that pathogenic mechanisms leading to muscle degeneration and subsequent activation of
regeneration cycles are already active in mdx mice at the age of two weeks, as evidenced by histo-
logical analysis of the percentages of centrally-nucleated myoﬁbers in SeC-MC-treated mice at the
beginning and the end of the treatment (Fig. 2A).2. Experimental design, materials and methods
2.1. Microencapsulation of SeC
The procedures for the isolation of Sertoli cells (SeC) from SPF-certiﬁed pre-pubertal Large White
pig testes, and SeC characterization and microencapsulation into sodium alginate are fully described
in Ref. [1].
2.2. Animals
Data were obtained in 2-week- or 12-month-old male mdx mice (C57BL/10ScSn-Dmdmdx/J, original
breeding from Jackson Laboratory) raised on a 12 h light/day cycle and a standard mouse diet. SeC-MC
or E-MC were injected into the peritoneal cavity of recipient mice by a sterile 16-gauge catheter under
general anesthesia. Equivalent amounts to 1.0106 SeC/g body weight in a concentration of
1.0107 SeC/ml in saline (NaCl 0.9%) were transplanted. The procedures and experiments on mice
were approved by the Ethics Committee of the Perugia University and the Italian Ministry of Health.
2.3. Morphological analyses
Muscles were isolated, formalin-ﬁxed and parafﬁn-embedded in order to maximally preserve
morphology. Muscle cross-sections measuring 4 mm were obtained and processed for standard hae-Fig. 1. SeC-MC ameliorate muscle morphology when i.p. injected into chronic dystrophic mice. (A–D) DIA from 12-month-old
mdx mice i.p. injected with SeC-MC (n¼6) or empty microcapsules (Mock) (n¼6) were analyzed three weeks after injection.
H&E (A) and Mallory (B) staining were used to reveal adipose tissue (arrow in A) and ﬁbrotic tissue (blue) inﬁltrate, respectively,
and MAC3 immunohistochemistry (C) was used to detect macrophages in DIA from SeC-MC-treated and mock-treated mice.
The average percentages (7SEM) of adipose tissue inﬁltrate, and ﬁbrotic and MAC3þ areas in mock- and SeC-MC-treated DIA
were determined (D). (E) Mdx mice treated as above were injected with Evans Blue Dye (EBD) 24 h before being sacriﬁced and
QF muscles were isolated, cryosectioned and analyzed for detection of EBD inﬁltration (red). Individual myoﬁbers were deli-
neated with laminin staining (green), and nuclei were counterstained with DAPI (blue). Shown are representative images.
Reported are the average percentages (7SEM) of EBD-positive myoﬁbers in each group. (F–K) TA muscles isolated from mice in
(A–D) were analyzed by H&E (F) or Mallory (G) staining, and MAC3 immunohistochemistry (H). The mean percentages (7SEM)
of ﬁbrotic and MAC3þ areas in mock- and SeC-MC-treated mice were determined (I). Utrophin expression and localization
were analyzed by Western blotting (J) and immunoﬂuorescence on frozen sections (K), respectively. The average relative
densities (7SEM) of utrophin bands with respect to α-actinin bands were determined (J). * and **, signiﬁcantly different from
mock-treated control at pr0.001 and pr0.01, respectively. Original magniﬁcation (A–C, E–G), 20 ; (H and K), 40 .
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S. Chiappalupi et al. / Data in Brief 5 (2015) 1015–10211020matoxylin/eosin (H&E) or Mallory staining. Quantiﬁcations on muscle sections were performed by
three independent operators blinded to treatments. Sections at 100 mm intervals for each muscle
were analyzed. The entire area of each section was evaluated to avoid bias. Areas with sectioning
artifacts (folds, tears, etc.) were avoided. After H&E staining, the percentages of undamaged, regen-
erating, regenerated, and necrotic myoﬁbers per section were manually counted by three indepen-
dent operators according to the following parameters: i) undamaged ﬁbers, identiﬁed by the presence
of peripheral nuclei; ii) regenerated ﬁbers, identiﬁed by normal size but with central nuclei; iii)
regenerating ﬁbers, identiﬁed by small size, basophilic cytoplasm and central nuclei; and, iv) necrotic
ﬁbers, identiﬁed by pale cytoplasm and phagocytosis. Areas of fat deposition were identiﬁed by the
evacuated spaces generated by the histochemical delipidation. The percentages of adipose tissue and
ﬁbrotic areas (blue, after Mallory staining) were measured using Scion Image 4.0.3.2 software (NIH,
Bethesda, USA). Slices were analyzed and photographed with a bright ﬁeld microscope (Olympus
BX51) equipped with a digital camera. Values reported are given as mean (7SEM) obtained from
multiple animals as speciﬁed in each ﬁgure. For the evaluation of myoﬁber necrosis mice were i.p.
injected with a 1% Evan's Blue Dye (EBD) solution (Sigma-Aldrich) at 1% volume relative to body mass
16–24 h prior to tissue sampling. Muscles were isolated and ﬂash frozen in a pre-cooled beaker of
isopentane placed in liquid nitrogen. Cryosections were ﬁxed in acetone at 20°C. An anti-laminin
antibody (Sigma-Aldrich, L9393; 1:50) followed by an AlexaFluor 488-conjugated anti-rabbit Ig G
(Invitrogen, 1:100) was used to mark individual myoﬁbers. Nuclei were counterstained with 40, 6-
diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Negative controls (not shown) bypassed the pri-
mary antibody treatment. The samples were analyzed by an epiﬂuorescence microscope (Leica
DMRB) equipped with a digital camera.
2.4. Immunohistochemistry and immunoﬂuorescence
Parafﬁn sections of muscles were cut at 4 mm, deparafﬁnized with xylene and rehydrated in a
graded ethanol series. Antigen retrieval was obtained by boiling for 1.5 h in 10 mM citric acid buffer
(pH 6.0), and depletion of endogenous peroxidase was accomplished by treatment with 3% H2O2.
Sections were washed with TBS, pH 7.4, incubated for 1 h with blocking buffer [BB; TBS containing
0.01% Tween-20 (T-TBS) and 10% HS]. MAC3 detection was obtained by an anti-MAC3 antibody (BD
Biosciences,1:50 in BB) followed by incubation with horseradish peroxidase (HRP)-conjugated anti-
rat Ig G antibody (Santa Cruz Biotechnology, 1:500). Sections were incubated with 0.01% 3,3-diami-
nobenzidine tetrahydrochloride (DAB), and 0.006% H2O2 in 50 mM Tris–HCl, pH 7.4. Nuclei were
counterstained with haematoxylin. The slices were then dehydrated, mounted with EuKitt mounting
medium (Electron Microscopy Sciences, USA), and analyzed and photographed with a bright ﬁeld
microscope (Olympus BX51) equipped with a digital camera. To detect utrophin in muscle tissue
(Fig. 2D), immunoﬂuorescence reactions on tissue slices were performed as above except that PBS, pH
7.4, and a different BB (i.e., 0.4% Triton-X-100, 10% donkey serum and 1% BSA in PBS) were used. A
mouse monoclonal anti-utrophin (8A4) antibody (Santa Cruz Biotechnology, sc-33700; 1:20 in BB)
was used as primary antibody, followed by a TRITC-conjugated anti-mouse IgG antibody (Sigma-
Aldrich, 1:50). Where indicated, acetone-ﬁxed cryosections (7 mm) were used to detect utrophin using
the same primary and secondary antibodies as above diluted in 1% BSA in PBS. Nuclei were coun-
terstained with DAPI. After rinsing, samples were mounted with ﬂuorescent mounting medium (DakoFig. 2. SeC-MC reduce muscle necrosis when i.p. injected into presymptomatic dystrophic mice. (A) Two-week-old mdx mice
were i.p. injected with E-MC (mock) (n¼6) or SeC-MC (n¼6). Three weeks after injection TA muscle morphology was analyzed
by haematoxylin/eosin staining (lower left panels) and the mean percentages (7SEM) of undamaged, centrally-nucleated, and
necrotic myoﬁbers were determined (lower right panels).TA muscles of untreated 2-week- and 5-week-oldmdxmice (n¼5 each
group) were analyzed in parallel (upper panels). (B) TA muscles from mock- and SeC-MC-treatedmdxmice in (A) were analyzed
for inﬁltrating macrophages by MAC3 immunohistochemistry (brown). The mean percentages (7SEM) of MAC3þ areas were
determined. (C) Utrophin expression was analyzed by Western blotting. The average relative densities (7SEM) of utrophin
bands with respect to α-actinin bands were determined. (D) Utrophin localization was determined by immunoﬂuorescence on
formalin-ﬁxed parafﬁn-embedded muscle tissue. Nuclei were counterstained with DAPI (blue). Shown are representative
images. *, signiﬁcantly different from control (pr0.001). Original magniﬁcation (A, B, and D), 40 .
S. Chiappalupi et al. / Data in Brief 5 (2015) 1015–1021 1021Corporation, Denmark) and viewed in an epiﬂuorescence microscope (Leica DMRB) equipped with a
digital camera.3. Western blotting
Muscle tissue was homogenized in 10 mM Tris, pH 7.4, 2.5% v/v sodium dodecyl sulfate (SDS),
100 mM dithiothreitol (DTT), in the presence of a mixture of protease inhibitors (Sigma-Aldrich). The
amount of protein in each sample was determined by Bradford assay, and equal amounts of protein
were size-separated by SDS–PAGE. The following primary antibodies were used: anti-utrophin (8A4)
(Santa Cruz Biotechnology, sc-33700; 1:500); anti-α-actinin (Sigma-Aldrich, cat. A7811; 1:1000). After
incubation with the appropriate HRP-conjugated secondary antibodies, the immune reaction was
developed by enhanced chemiluminescence (SuperSignal West Pico, Thermo Scientiﬁc). C-DiGit Blot
Scanner (LI-COR, USA) was used for the analysis of blots.4. Statistical analysis
Quantitative data are means7SEM of at least three independent experiments. Representative
experiments are shown unless stated otherwise. The data were subjected to analysis of variance
(ANOVA) with SNK post-hoc analysis using a statistical software package (GraphPad Prism version
4.00, GraphPad).Acknowledgments
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